SCTX (Scribe Therapeutics) PS Ratio: 83.02 (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $22.00
View Full Analysis

What is Scribe Therapeutics PS Ratio?

Scribe Therapeutics SCTX -13.40% 8 PS Ratio is 83.02 as of Jul. 26, 2026. GuruFocus rates SCTX with a GF Score™ of 8/100. Among 930 Biotechnology companies, Scribe Therapeutics ranks worse than 107526.77% on this metric.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Scribe Therapeutics's share price is $22.00. Scribe Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.27. Hence, Scribe Therapeutics's PS Ratio for today is 83.02.

The historical rank and industry rank for Scribe Therapeutics's PS Ratio or its related term are showing as below:

SCTX's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9
* Ranked among companies with meaningful PS Ratio only.

Scribe Therapeutics's Revenue per Sharefor the three months ended in Mar. 2026 was $0.27. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.27.

Back to Basics: PS Ratio


Scribe Therapeutics  (NAS:SCTX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Scribe Therapeutics PS Ratio Related Terms


Scribe Therapeutics PS Ratio Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics PS Ratio Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
PS Ratio
0.00 0.00

Scribe Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
PS Ratio 0.00 0.00 0.00 0.00

SCTX vs : PS Ratio Comparison

For the Biotechnology subindustry, Scribe Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scribe Therapeutics PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scribe Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Scribe Therapeutics's PS Ratio falls into.


SCTX
8GF Score
Scribe Therapeutics Inc SCTX
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Scribe Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=22.00/0.265
=83.02

Scribe Therapeutics's Share Price of today is $22.00.
Scribe Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.27.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 83.02 mean?
Scribe Therapeutics (SCTX) has a PS Ratio of 83.02 as of Jul. 26, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Scribe Therapeutics and its competitors. According to the industry distribution chart, Scribe Therapeutics ranks #999999 out of 930 companies in the Biotechnology industry.
Is Scribe Therapeutics' PS Ratio too high?
Scribe Therapeutics' current PS Ratio is 83.02. The Biotechnology industry median PS Ratio is 9.00. Scribe Therapeutics' value of 83.02 is 822.4% above this industry median. Based on the distribution chart, Scribe Therapeutics ranks #999999 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' PS Ratio compare to ?
According to the Biotechnology industry distribution chart, Scribe Therapeutics ranks #999999 out of 930 companies for PS Ratio. This places Scribe Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.00. Scribe Therapeutics' value of 83.02 is 822.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.00, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scribe Therapeutics's current PS Ratio of 83.02 is 822.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Scribe Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scribe Therapeutics's current PS Ratio is 83.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current PS Ratio of 83.02. The current PS Ratio is 83.02 and 822.4% above the Biotechnology industry median of 9.00. Scribe Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current PS Ratio is 83.02 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Comparable Companies
Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.00
Price